Accuray Incorporated (ARAY) - Total Liabilities
Based on the latest financial reports, Accuray Incorporated (ARAY) has total liabilities worth $401.98 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Accuray Incorporated's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Accuray Incorporated - Total Liabilities Trend (2002–2026)
This chart illustrates how Accuray Incorporated's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Accuray Incorporated total assets.
Accuray Incorporated Competitors by Total Liabilities
The table below lists competitors of Accuray Incorporated ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bellway PLC
LSE:BWY
|
UK | GBX1.54 Billion |
|
Uvre Ltd
AU:UVA
|
Australia | AU$75.12K |
|
HarbourVest Global Private Equity Ltd
LSE:HVPE
|
UK | GBX440.67 Million |
|
Riverstone Credit Opportunities Income Plc
LSE:RCOI
|
UK | $586.00K |
|
Franklin Wireless Corp
NASDAQ:FKWL
|
USA | $13.99 Million |
|
Financiere Marjos SA
PA:FINM
|
France | €1.22 Million |
|
Kyntra Bio, Inc.
NASDAQ:KYNB
|
USA | $140.40 Million |
Liability Composition Analysis (2002–2026)
This chart breaks down Accuray Incorporated's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Accuray Incorporated to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 9.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.91 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Accuray Incorporated's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Accuray Incorporated (2002–2026)
The table below shows the annual total liabilities of Accuray Incorporated from 2002 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | $401.98 Million | +3.32% |
| 2025-06-30 | $389.07 Million | -8.14% |
| 2024-06-30 | $423.54 Million | -0.47% |
| 2023-06-30 | $425.56 Million | +1.40% |
| 2022-06-30 | $419.66 Million | +2.04% |
| 2021-06-30 | $411.26 Million | -3.75% |
| 2020-06-30 | $427.29 Million | +10.04% |
| 2019-06-30 | $388.31 Million | +17.64% |
| 2018-06-30 | $330.10 Million | -8.29% |
| 2017-06-30 | $359.93 Million | -12.08% |
| 2016-06-30 | $409.37 Million | +3.85% |
| 2015-06-30 | $394.19 Million | -0.62% |
| 2014-06-30 | $396.64 Million | +7.46% |
| 2013-06-30 | $369.09 Million | +37.06% |
| 2012-06-30 | $269.30 Million | +24.99% |
| 2011-06-30 | $215.46 Million | +131.41% |
| 2010-06-30 | $93.11 Million | -22.72% |
| 2009-06-30 | $120.48 Million | -26.64% |
| 2008-06-30 | $164.24 Million | -20.53% |
| 2007-06-30 | $206.67 Million | -5.84% |
| 2006-06-30 | $219.48 Million | +53.45% |
| 2005-06-30 | $143.03 Million | +118.72% |
| 2003-06-30 | $65.39 Million | +83.92% |
| 2002-06-30 | $35.56 Million | -- |
About Accuray Incorporated
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation t… Read more